Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients

Table 3 Logistic regression analysis during the first 12 wk of combination therapy

Variable	Univariate		Multivariate
	OR (95%CI)	P value	OR (95%CI)	P value
Sex (female)	0.49 (0.1-2.4)	0.386	4.7 (0.9-26.4)	0.123
Age (≥ 40 yr)	0.66 (0.24-1.8)	0.421	1.02 (0.9-1.1)	0.462
BMI ( ≤ 24)	2.03 (0.82-5.01)	0.124	1.2 (1-1.5)	0.068
Baseline Hb (< 15)	0.14 (0.04-0.49)	0.002	0.8 (0.5-1.2)	0.610
Baseline plt (< 200)	0.26 (0.1-0.65)	0.004	0.9 (0.9-1)	0.073
ITPA genotype (CC)	6.36 (1.24-32.41)	0.025	0.4 (0.04-4.08)	0.671
RBV dose ≥ 80%	0.08 (0.01-0.3)	0.0009	0.87 (0.82-0.92)	0.00002

OR: Odds ratio; BMI: Body mass index; Hb: Hemoglobin; plt: Platelet; ITPA: Inosine triphosphate pyrophosphatase; RBV: Ribavirin.